EU/3/08/584: Orphan designation for the treatment of soft tissue sarcoma


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2015 on request of the sponsor.

On 3 December 2008, orphan designation (EU/3/08/584) was granted by the European Commission to Ziopharm Oncology Limited, United Kingdom, for palifosfamide for the treatment of soft tissue sarcoma.

Key facts

Active substance
Intended use
Treatment of soft tissue sarcoma
Orphan designation status
EU designation number
Date of designation

Ziopharm Oncology Limited
3rd Floor
24 Chiswell Street
London EC1Y 4YX
United Kingdom
Tel. +44 (0)20 7382 1820
Fax +44 (0)20 7382 1821

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating